InSilicoTrials and Axoltis Pharma are teaming up to advance the development of NX210c, the latter’s lead candidate for treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Axoltis will use InSilicoTrials’ simulation platform to see how well NX210c works in virtual simulations that mimic brain and…
News
A professor at Massachusetts General Hospital and Harvard Medical School was awarded $10,000 by Mass General Brigham (MGB) for her work to restore the levels of stathmin-2, a protein that is disrupted in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a related neurodegenerative condition, as a possible…
New Brunswick is reimbursing, through its public health insurance program, the cost of Albrioza (sodium phenylbutyrate and ursodoxicoltaurine) for eligible residents living with amyotrophic lateral sclerosis (ALS). The Canadian province is the country’s fourth to provide public coverage for the oral therapy — marketed in the U.S.
Six months of treatment with clenbuterol, an asthma medication, slowed disease progression in adults with amyotrophic lateral sclerosis (ALS), according to data from a small U.S.-based Phase 2 clinical trial. Despite these promising preliminary findings, more than half the participants withdrew from the study due to side effects. “Nonetheless,…
It’s long been known that some molecules are misplaced in the nerve cells that progressively die in amyotrophic lateral sclerosis (ALS), but a new study shows this affects hundreds of different molecules, not just a handful, as previously thought. “This research represents a shift in our thinking about what…
Athira Pharma’s experimental therapy ATH-1105 shows anti-inflammatory and neuroprotective effects, promoting neuron growth and reducing damage associated with mechanisms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a related condition. The small molecule reduced inflammation and the buildup of a faulty version of TDP-43, a protein that’s…
A new home-based neurocognitive platform from Cumulus Neurosciences is feasible to use and patient-friendly, and shows potential to identify cognitive problems and to discriminate between people with amyotrophic lateral sclerosis (ALS), those with frontotemporal dementia (FTD), and healthy individuals. That’s according to preliminary data from a first-in-class study,…
Dimethyl fumarate (DMF) — an oral medication approved for multiple sclerosis — and H-151, an experimental treatment, can suppress inflammatory and abnormal immune pathways thought to be involved in sporadic amyotrophic lateral sclerosis (ALS). These are the findings of a study using immune cells from sporadic ALS patients…
An ongoing Phase 1 clinical trial of QurAlis’ experimental therapy QRL-201 in people with amyotrophic lateral sclerosis (ALS) is expected to open in the U.K. by the end of the year. The announcement follows the trial’s clearance by the country’s Medicines and Healthcare Products Regulatory Agency. “We look…
With an aim to share expertise and diminish duplicative research and care efforts in amyotrophic lateral sclerosis (ALS), two nonprofits — EverythingALS and CureALS — are combining operations on the EverythingALS platform, with an emphasis on research. The new single nonprofit also will tackle efforts to find…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients